Cayman Chemical, a global provider of life science research tools, and Akadeum Life Sciences, a leader in buoyancy-based cell ...

In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with ...

While AMT-130 could result in meaningful revenue for ClearPoint, the Huntington's opportunity is relatively modest compared ...

Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio ...

One oral presentation and five poster presentations will highlight exciting progress in AskBio’s pipeline and advancements in the company’s manufacturing technologies AskBio Inc. (AskBio), a gene ...

Cirrus’ lead program is a novel AAV gene therapy designed to restore IRAK-M, a central regulator of the eye’s immune homeostasis, so as to ...

PHILADELPHIA, October 02, 2025--iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo ...

Takeda is looking to offload its cell therapy platform and preclinical assets to a yet-unidentified external partner. 137 ...

Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA ...

French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in ...